Zobrazeno 1 - 10
of 39
pro vyhledávání: '"Juha Laine"'
Autor:
Sarah Pugh, Matt Wasserman, Margaret Moffatt, Susana Marques, Juan Manuel Reyes, Victor A. Prieto, Davy Reijnders, Mark H. Rozenbaum, Juha Laine, Heidi Åhman, Raymond Farkouh
Publikováno v:
Infectious Diseases and Therapy, Vol 9, Iss 2, Pp 305-324 (2020)
Abstract Introduction Widespread use of ten-valent (Synflorix™, GSK) or 13-valent (Prevenar 13™; Pfizer) conjugate vaccination programs has effectively reduced invasive pneumococcal disease (IPD) globally. However, IPD caused by serotypes not con
Externí odkaz:
https://doaj.org/article/e0bd0f8cea3d44338a870cad37762551
Publikováno v:
BMC Public Health, Vol 17, Iss 1, Pp 1-6 (2017)
Abstract Background Varenicline is an efficacious medicine for smoking cessation (SC) but little is known about the characteristics of varenicline users. This study examined the characteristics of first-time (naïve) varenicline users in Finland and
Externí odkaz:
https://doaj.org/article/c0940d76a5984ad4a9ecde7d263ea8a5
Publikováno v:
Journal of the Finnish Economic Association
A non-trivial fraction of people cannot afford to buy pharmaceutical products at unregulated market prices. This paper analyses the public insurance of a patent-protected pharmaceutical product in terms of price controls and socially optimal third-de
Autor:
VA Prieto, Juha Laine, Mark H. Rozenbaum, Matt Wasserman, Heidi Åhman, Davy Reijnders, Sarah J. Pugh, Margaret Moffatt, Susana Castro Marques, J. Reyes, Raymond Farkouh
Publikováno v:
Infectious Diseases and Therapy
Infectious Diseases and Therapy, Vol 9, Iss 2, Pp 305-324 (2020)
Infectious Diseases and Therapy, Vol 9, Iss 2, Pp 305-324 (2020)
Introduction Widespread use of ten-valent (Synflorix™, GSK) or 13-valent (Prevenar 13™; Pfizer) conjugate vaccination programs has effectively reduced invasive pneumococcal disease (IPD) globally. However, IPD caused by serotypes not contained wi
Exploring the costs of a 13-valent pneumococcal conjugate vaccination program for home care patients
Publikováno v:
CURRENT MEDICAL RESEARCH AND OPINION. 34(12):2089-2094
The city of Joensuu in Finland vaccinated 409 elderly home care patients with the 13-valent pneumococcal conjugate vaccine (PCV13) in autumn 2012. All home care patients were also eligible for a seasonal influenza vaccine. The objective of this retro
Autor:
Kirsi Kautiainen, Juha Laine, Kari Linden, Jarmo Hahl, Helena Liira, Mikko Puhakka, Heikki Ekroos
Publikováno v:
Journal of Medical Economics. 20:246-252
One quit attempt with varenicline has been found to be a cost-effective smoking cessation intervention. The purpose of this study was to analyze varenicline's cost-effectiveness in patients who relapse during or after the first treatment. A compariso
Publikováno v:
Biologics : Targets & Therapy
Juha Laine,1 T Sakari Jokiranta,2,3 Kari K Eklund,4,5 Merja Väkeväinen,1 Kari Puolakka6 1Pfizer Oy, Helsinki, 2United Medix Laboratories Ltd, Espoo, 3Research Programs Unit, Immunobiology, 4Department of Rheumatology, University of Helsinki, 5Helsi
Publikováno v:
BMC Public Health
BMC Public Health, Vol 17, Iss 1, Pp 1-6 (2017)
BMC Public Health, Vol 17, Iss 1, Pp 1-6 (2017)
Background: Varenicline is an efficacious medicine for smoking cessation (SC) but little is known about the characteristics of varenicline users. This study examined the characteristics of first-time (naïve) varenicline users in Finland and compared
Publikováno v:
Journal of Evaluation in Clinical Practice. 20:333-341
Rationale, aims and objectives Invasive pneumococcal diseases (IPD) are associated with substantial burden in adults (≥50 years). Moreover, adults with vascular, metabolic or respiratory diseases have been shown to have a 3–6 times higher risk of
Publikováno v:
Value in Health. 18(7)